Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Arvinas (ARVN) announced it will present first-in-human data from its Phase 1 study of ARV-102 at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) in Vienna, Austria, April 1-5, 2025.
The presentation will showcase data from both single-ascending and multiple-ascending dose portions of the study in healthy volunteers. ARV-102 is a PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a protein linked to Parkinson's disease and progressive supranuclear palsy.
The presentation, titled 'First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102,' is scheduled for April 4, 2025, at 3:20 p.m. CET during the LRRK2, Alpha-Synuclein, Parkin symposium session.
Arvinas (ARVN) ha annunciato che presenterà i dati di fase 1 della sua ricerca su ARV-102 durante la Conferenza Internazionale sulle Malattie di Alzheimer e Parkinson (AD/PD™) a Vienna, Austria, dal 1 al 5 aprile 2025.
La presentazione mostrerà i dati sia della parte a dose ascendente singola che di quella a dose ascendente multipla dello studio su volontari sani. ARV-102 è un degrader PROteolysis TArgeting Chimera (PROTAC) che mira alla chinasi 2 a ripetizione ricca di leucina (LRRK2), una proteina associata alla malattia di Parkinson e alla paralisi sopranucleare progressiva.
La presentazione, intitolata 'Studio di Prima Umanità per Valutare la Sicurezza, la Farmacocinetica e la Farmacodinamica di ARV-102,' è programmata per il 4 aprile 2025, alle 15:20 CET durante la sessione del simposio LRRK2, Alpha-Sinucleina, Parkin.
Arvinas (ARVN) anunció que presentará datos de su estudio de fase 1 sobre ARV-102 en la Conferencia Internacional sobre Enfermedades de Alzheimer y Parkinson (AD/PD™) en Viena, Austria, del 1 al 5 de abril de 2025.
La presentación mostrará datos tanto de la parte de dosis ascendente única como de la parte de dosis ascendente múltiple del estudio en voluntarios sanos. ARV-102 es un degradador PROteolysis TArgeting Chimera (PROTAC) que tiene como objetivo la quinasa 2 rica en repeticiones de leucina (LRRK2), una proteína vinculada a la enfermedad de Parkinson y a la parálisis supranuclear progresiva.
La presentación, titulada 'Estudio de Primera en Humanos para Evaluar la Seguridad, Farmacocinética y Farmacodinamia de ARV-102,' está programada para el 4 de abril de 2025, a las 15:20 CET durante la sesión del simposio LRRK2, Alfa-Sinucleína, Parkin.
Arvinas (ARVN)는 2025년 4월 1일부터 5일까지 오스트리아 비엔나에서 열리는 알츠하이머 및 파킨슨병 국제 회의(AD/PD™)에서 ARV-102의 1상 연구에 대한 인간 첫 데이터 발표를 할 것이라고 발표했습니다.
발표에서는 건강한 자원봉사자들을 대상으로 한 단일 용량 상승 및 다중 용량 상승 부분의 데이터를 보여줄 것입니다. ARV-102는 파킨슨병 및 진행성 수핵마비와 관련된 단백질인 리신-리치 반복 키나제 2(LRRK2)를 표적으로 하는 PROteolysis TArgeting Chimera (PROTAC) 분해제입니다.
'ARV-102의 안전성, 약리학적 동태 및 약리학적 작용을 평가하기 위한 첫 번째 인간 연구'라는 제목의 발표는 2025년 4월 4일 오후 3시 20분 CET에 LRRK2, 알파-시뉴클레인, 파킨 심포지엄 세션에서 예정되어 있습니다.
Arvinas (ARVN) a annoncé qu'elle présentera des données de première utilisation chez l'homme de son étude de phase 1 sur ARV-102 lors de la Conférence Internationale sur les Maladies d'Alzheimer et de Parkinson (AD/PD™) à Vienne, en Autriche, du 1er au 5 avril 2025.
La présentation mettra en avant des données provenant à la fois de la partie à dose unique ascendante et de la partie à doses multiples ascendantes de l'étude sur des volontaires en bonne santé. ARV-102 est un dégradant PROteolysis TArgeting Chimera (PROTAC) ciblant la kinase 2 riche en leucine (LRRK2), une protéine liée à la maladie de Parkinson et à la paralysie supranucléaire progressive.
La présentation, intitulée 'Étude de Première Utilisation chez l'Homme pour Évaluer la Sécurité, la Pharmacocinétique et la Pharmacodynamie de ARV-102,' est prévue pour le 4 avril 2025 à 15h20 CET lors de la session du symposium LRRK2, Alpha-Synucléine, Parkin.
Arvinas (ARVN) gab bekannt, dass es auf der Internationalen Konferenz über Alzheimer- und Parkinson-Krankheiten (AD/PD™) in Wien, Österreich, vom 1. bis 5. April 2025 die ersten Daten aus seiner Phase-1-Studie zu ARV-102 präsentieren wird.
Die Präsentation wird Daten sowohl aus der einzelnen Dosissteigerung als auch aus der mehrfachen Dosissteigerung des Studienabschnitts mit gesunden Freiwilligen zeigen. ARV-102 ist ein PROteolysis TArgeting Chimera (PROTAC) Abbauprodukt, das auf die Leucin-reiche Wiederholungs-Kinase 2 (LRRK2) abzielt, ein Protein, das mit der Parkinson-Krankheit und der progressiven supranukleären Lähmung in Verbindung steht.
Die Präsentation mit dem Titel 'Erste Mensch-Studie zur Bewertung der Sicherheit, Pharmakokinetik und Pharmakodynamik von ARV-102' ist für den 4. April 2025 um 15:20 Uhr MEZ während der LRRK2, Alpha-Synuclein, Parkin Symposium-Session geplant.
- First-in-human data readout indicates progression in clinical development pipeline
- Presentation at major international conference provides visibility for ARV-102 program
- None.
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –
NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), April 1-5, 2025 in Vienna, Austria.
ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy.
Presentation details are as follows:
Session Title: First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Males (ID:1963)
Session Type: Symposium: LRRK2, Alpha-Synuclein, Parkin: Diagnosis and Therapeutic Targets (ID:83)
Date: Friday, April 4, 2025
Lecture Time: 3:20 p.m. - 3:35 p.m. CET
The full abstract can be accessed via the AD/PD 2025 online interactive program.
About ARV-102
ARV-102 is an oral, brain penetrant investigational PROTAC designed to degrade Leucine-rich repeat kinase 2 (LRRK2) which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 have been implicated in the pathogenesis of neurological diseases including and Parkinson’s disease and progressive supranuclear palsy.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential therapeutic benefits of ARV-102 and the development of protein degradation therapies through Arvinas’ PROTAC protein degrader platform. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to whether Arvinas will be able to successfully conduct and complete development of ARV-102, including whether Arvinas initiates and completes clinical trials for ARV-102 and receives results from its clinical trials on its expected timelines or at all; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
kirsten.owens@arvinas.com
FAQ
What is ARV-102 and what disease does it target?
When will Arvinas (ARVN) present the Phase 1 data for ARV-102?
What type of data will be presented for ARVN's ARV-102 at AD/PD 2025?
What is the mechanism of action of Arvinas' ARV-102?
